Our Science Agenda
The science agenda for the CPCRA focuses
on answering key clinical management questions that face providers
and patients every day. The agenda is constructed around a core
of antiretroviral treatment trials. These trials are complemented
with substudies and other trials focused on issues of current interest.
The following diagram illustrates how the studies are interconnected.
In the diagram the core antiretroviral
strategy trials are represented by yellow boxes in the center of
the figure. The levels of studies target persons in different stages
of disease.
- The Flexible Initial Retroviral
Suppression Trial (FIRST; CPCRA 058) targets persons who are initiating
therapy while Nelfinavir versus Ritonavir (NvR; CPCRA 042) targets
those who are beginning their first protease inhibitor (PI).
- The SMART* study explores strategic
options to antiretroviral use.
- The Multidrug-Resistant (MDR-HIV;
CPCRA 064) study targets persons with progressive disease due
to multi-drug resistant virus.
The Long-Term Monitoring (LTM; CPCRA
060) study targets patients at any stage of disease and treatment
and provides a means of monitoring patients over years of follow-up,
seeking data on the late outcomes of clinical therapy.
|
